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Introduction
Urinary tract infections (UTIs) are one of the most common bacterial infections and are likely to 
become recurrent. In young women, the risk of relapse within 6 months is 24%, which may lead to 
the development of a chronic infection.1  
Unlike in the acute condition, chronic UTI patients often fail to respond to antibiotic treatment. 
Our clinical experience is that antibiotics predicted to be effective on culture may be unsuccessful 
in the clinical setting, while antibiotics predicted to be unsuitable can succeed. This suggests that
phenotypic sensitivity and resistance profiles of strains that are actually causing the infection 
might differ from profiles obtained in diagnostic laboratory conditions.  
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1. Antibiotics administration to chronic UTI 
patients. 
2. Collection of the urine sample from the 
patient: it is stored at 4 degrees until processing, 
which takes place within 5h from collection. 
3. Urine sample processing and plating on 
selective media: after 24h the colonies are 
isolated on non-selective media and the species 
are identified.   
4. Antibiotic susceptibility testing (AST): 
multiple isolates are independently tested against 
each antibiotic administered to the patients. 
Different colonies of the same species are tested 
in parallel to reveal possible differences among 
strains. 
5. DNA extraction
6. DNA sequencing and genome assembly: 
this step would highlight main differences in 
genome organisation compared with control 
strains. 
Hypothesis
In this study we hypothesized that diagnostic growth media can influence the outcome of 
sensitivity testing, leading the same strain to show different Minimum Inhibitory Concentrations
(MICs) for a given antibiotic depending on the nutrients available. 
We decided to test this hypothesis using the following approaches:
• The use of a more biologically relevant condition (i.e. urine, human bladder organoid) could 
reveal sensitivity profiles that are more likely to match what happens in chronic UTI patients. 
• The application of Next Generation Sequencing (NGS) techniques could reveal the genomic 
and transcriptional signatures of pathogens after antibiotic administration. 
Results 
• Evolution of resistance to amoxicillin-clavulanic acid (AMC) was performed using the 
clinical isolate Escherichia coli 10129 in either M9, ISO or LB medium. A significant reduction in 
cell density was observed during incubation in M9 containing sub-inhibitory concentrations of 
AMC (see Fig. 1) and it was not possible to recover any resistant isolate from agar plates. 
• MICs of evolved strains in different media showed very high variability in sensitivity profiles 
(see Fig 2). 
• Culturing of ancestral and evolved strains in LB and the human bladder organoid showed 
discrepancies in relative fitness and growth in the two systems (see Fig. 3). 
Conclusions 
• Type of medium has a direct effect on the exhibition of sensitivity profiles: this finding may 
have implications for the interpretation of diagnostic testing and for treatment outcome. 
• The use of a human bladder organoid and NGS techniques may shed light on why chronic 
UTIs can be difficult to treat. 
• We may need to look beyond the genomic sequence and consider expression profiles when 
unravelling host-pathogen interactions in the clinical setting. 
7. Test each strain in a human bladder 
organoid developed previously in the lab.3
Treatment with the antibiotics used in the clinic 
using a more biologically relevant environment 
would better mimic the conditions found in 
patients. 
8. RNA extraction from bacteria grown in the 
bladder organoid. 
9. RNA sequencing: identification of 
transcriptional signatures of key genes that might 
explain why the AST traditionally performed in 
diagnostic laboratories is not able to predict the 
sensitivity profiles in the clinical setting.  
Fig. 2 Circular barplot chart showing the MIC values of the E. coli 10129 and three evolved resistant 
strains. Clinical breakpoint for sensitivity and resistance is 8 and 16µg/ml, respectively. The scale represents the 
MIC value. 2
Fig.3 Relative fitness and growth of E. coli isolates. (A) Relative fitness of E. coli 10129-derived resistant 
isolates ISO_2, LB_2 and LB_5 compared to the ancestral isolate in LB. (B) Relative fitness of E. coli 10129-
derived resistant isolates ISO_2, LB_2 and LB_5 compared with the ancestral isolate in urothelial organoids. 
Error bars represent standard error of the mean.2
Fig. 1 Difference in cell density (Log CFU/ml) of E. coli 10129 after 24h exposure with sub-inhibitory 
concentrations of AMC. Compared with the initial inoculum, there was a significant increase of E. coli 10129 
cell density of 1.03 log CFU/ml in LB in the presence of AMC (p-value = 0.0235), while there was an insignificant 
growth of 0.592 log CFU/ml in ISO containing AMC (p-value = 0.1339). Following exposure of E. coli 10129 to 
AMC in M9, we observed a significant reduction in cell density of 5.049 log CFU/ml (p-value < 0.0001) and we 
did not recover any resistant isolates from agar plates containing 8µg/ml or 16µg/ml AMC. Error bars represent 
the standard error of the mean.2
